BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
4.740
+0.060 (1.28%)
Nov 18, 2025, 3:18 PM EST - Market open
BioNexus Gene Lab Revenue
BioNexus Gene Lab had revenue of $2.54M in the quarter ending September 30, 2025, a decrease of -3.29%. This brings the company's revenue in the last twelve months to $9.47M, up 2.22% year-over-year. In the year 2024, BioNexus Gene Lab had annual revenue of $9.51M, down -2.66%.
Revenue (ttm)
$9.47M
Revenue Growth
+2.22%
P/S Ratio
0.89
Revenue / Employee
$315,500
Employees
30
Market Cap
8.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.51M | -260.16K | -2.66% |
| Dec 31, 2023 | 9.77M | -1.16M | -10.60% |
| Dec 31, 2022 | 10.93M | -2.43M | -18.21% |
| Dec 31, 2021 | 13.36M | 1.97M | 17.31% |
| Dec 31, 2020 | 11.39M | 11.26M | 8,872.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rio Tinto Group | 53.73B |
| BHP Group | 51.26B |
| CRH plc | 36.90B |
| Linde | 33.50B |
| Freeport-McMoRan | 26.00B |
| The Sherwin-Williams Company | 23.28B |
| Newmont | 21.50B |
| Ecolab | 15.89B |
BGLC News
- 6 days ago - BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization - GlobeNewsWire
- 8 days ago - BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities - GlobeNewsWire
- 4 weeks ago - BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc. - GlobeNewsWire
- 3 months ago - BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology - GlobeNewsWire
- 7 months ago - BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness - GlobeNewsWire
- 7 months ago - BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory - GlobeNewsWire
- 9 months ago - BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy - GlobeNewsWire
- 9 months ago - BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper - GlobeNewsWire